Patents Examined by Zachary J Miknis
  • Patent number: 11207385
    Abstract: In some aspects, the present disclosure provides compositions and methods for treating disease, e.g., inflammatory disease. Compositions herein comprise one or more polypeptide fragments of proopiomelanocortin or variants thereof. The one of more polypeptide fragments of proopiomelanocortin or variants thereof may be linked by a linker, e.g., a peptide linker, to form a fusion polypeptide.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: December 28, 2021
    Assignee: Aequus Biopharma, Inc.
    Inventors: Ronald Berenson, Christopher H. Clegg
  • Patent number: 11202817
    Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: December 21, 2021
    Assignee: Cornell University
    Inventors: Gang Lin, Carl Nathan, Pradeep K. Singh
  • Patent number: 11202749
    Abstract: The present disclosure relates to HAPLN1 protein of an aged individual. The HAPLN1 protein exhibits reduced expression with aging, and when administered, its effect in alleviating and reversing skin aging including wrinkles is excellent. Therefore, by exploiting the difference in expression, provided are a biomarker composition for measuring skin aging, capable of diagnosing skin aging; a kit; and a method of screening for skin aging alleviating agents, comprising detecting the expression level of HAPLN1 protein or HAPLN1 gene. In addition, provided are a pharmaceutical composition, cosmetic composition, or health functional food for preventing or alleviating skin aging, and a cosmetic composition or health functional food for alleviating wrinkles, each containing any one or more selected from the group consisting of HAPLN1 protein, a gene encoding the same, and an effective agent for promoting the expression or activating the functions of HAPLN1 protein or gene.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 21, 2021
    Assignee: HAPLNSCIENCE INC.
    Inventors: Dae Kyong Kim, Zhicheng Fu, Moon Jung Back
  • Patent number: 11197912
    Abstract: Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions are also suitable for treating and/or preventing COVID-19 and influenza. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: December 14, 2021
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Jianjie Ma, Jacob S. Yount, Matthew A. Sermersheim, Adam D. Kenney, Xinyu Zhou, Bryan A. Whitson, Nahush A. Mokadam, Tao Tan, Chuanxi Cai
  • Patent number: 11192930
    Abstract: The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat feline diabetes.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: December 7, 2021
    Assignee: Askton Bioscences Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion
  • Patent number: 11186609
    Abstract: The present invention provides a method for preparing S-Bz-MAG3 as a precursor of contrast media. Thioglycolic acid and benzoyl chloride are taken for the thiol protection reaction. Next, N,N?-dicyclohexylcarbodiimide and N-hydroxysuccinimide are converted to corresponding ester compounds. The corresponding ester compounds then react with triglycine by amide bonding reaction. The product of the reaction is recrystallized using acetone, filtered, and finally flushed using flushing agent to give the final product. This is a bifunctional chelator and can be bridged with 99mTc and 186/188Re effectively and applied to nuclear medicine imaging and tumor radiotherapy. By taking advantage of fewer synthesis steps and ease of operations, complicated separation and purification reactions can be reduced and thus achieving highly productivity of S-Bz-MAG3.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: November 30, 2021
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.
    Inventors: Ching-Yun Lee, Yu Chang, Cheng-Fang Hsu
  • Patent number: 11186625
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 30, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla
  • Patent number: 11154636
    Abstract: Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as Bacillus anthracis and Yersenia pestis. The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: October 26, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Minkyu Kim, Christopher P. Camp
  • Patent number: 11156614
    Abstract: The present invention is related to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising limulus amebocyte lysate (LAL) and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample; wherein the LAL is substantially free of coagulogen. The method also relates to compositions and kits comprising LAL substantially free of coagulogen, and methods of making such.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 26, 2021
    Assignee: Lonza Walkersville, Inc.
    Inventors: Candice Stumbaugh, David S. Herbst, Kenneth E. Nichols, Jr.
  • Patent number: 11149067
    Abstract: The present invention pertains to an improved chemical synthesis method for Ahp-cyclodepsipeptides which allows straight forward and easy synthesis of tailor-made Ahp-cyclodepsipeptides. The invention further provides Ahp-cyclodepsipeptides for use as HTRA protease inhibitors and their medical use.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 19, 2021
    Assignee: UNIVERSITÄT DUISBURG-ESSEN
    Inventors: Markus Kaiser, Steffen Köcher, Juliana Rey, Jens Bongard, Michael Ehrmann, Sarah Resch
  • Patent number: 11129871
    Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions to treat or prevent an endoplasmic reticulum (ER) stress-mediated kidney disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an ER calcium channel stabilizing agent or an ER stress modulating agent (e.g., mesencephalic astrocyte-derived neurotrophic factor (MANF), compound K201).
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 28, 2021
    Assignee: Washington University
    Inventors: Ying Chen, Fumihiko Urano, Yeawon Kim, Sun-Ji Park
  • Patent number: 11123399
    Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: September 21, 2021
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
  • Patent number: 11123437
    Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.
    Type: Grant
    Filed: January 26, 2020
    Date of Patent: September 21, 2021
    Assignee: Mainline Biosciences, Inc.
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 11117932
    Abstract: Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 14, 2021
    Assignees: The Hong Kong Polytechnic University, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Xuezhen Zhu, Yu-Wai Chen, Tak Hang William Chan, Ming Cheung Chow
  • Patent number: 11104703
    Abstract: Described are compounds for targeting proteases, e.g. serine proteases and their use in the diagnostic methods and methods for treatment of respiratory diseases such as cystic fibrosis. The compounds have the structure [H]—[B]-[A]; wherein [H] is a hydrophilic group, [B] is a subsite recognition group and [A] is a binding group; wherein A has the formula: —C(0)—CH2—NR1—COOR2 and wherein [B] has the structure: (i) —[CO—CH2—NR3]m-, or (ii) -[AA1-AA2]- or (iii) -(AA1-C0-CH2NR3)— or (iv) —(CO—CH2—NR3-AA1)- or (v) —(C0—CH2—NR4-AA1-AA3)-.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 31, 2021
    Assignee: The Queen's University of Belfast
    Inventors: Brian Walker, Lorraine Martin, Timothy Ferguson
  • Patent number: 11072637
    Abstract: The present invention provides a walnut oligopeptide powder, a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt % or higher, in which 95% or more of the peptides have a molecular weight of less than 1,500 Da. The method includes extracting walnut proteins using a highly efficient countercurrent extraction process, and subjecting the extract to filtration, enzymolysis, purification with a microfiltration membrane and an ultrafiltration membrane, concentrating, and spray drying to obtain the oligopeptide powder. The oligopeptide powder has an anti-oxidant activity and provides a protective effect for a neuron, and thus can ameliorate or treat memory deterioration and relieve fatigue.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: July 27, 2021
    Assignee: SINPHAR TIAN-LI (HANGZHOU) PHARMACY COMPANY LIMITED
    Inventors: Zhaori Wang, Mingchuan Liu, Shengjie Yang, Da Hong, Jinping Yang
  • Patent number: 11058746
    Abstract: The present invention provides a method of preventing or treating fibrosis in a subject, comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma lucidum, Ganoderma lucidum, Ganoderma tsugae, Ganoderma microsporum or Ganoderma sinensis to the subject, thereby preventing or treating a fibrosis.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 13, 2021
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Cheng-Chia Yu
  • Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 11034727
    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: June 15, 2021
    Assignee: TRANSFERT PLUS, S.E.C.
    Inventors: Richard Béliveau, Borhane Annabi, Michel Demeule, Alain Larocque, Jean-Christophe Currie, Cyndia Charfi
  • Patent number: 11033609
    Abstract: The invention relates to cyclic polypeptides derived from the C-terminus of acetylcholinesterase for use in treating or preventing cancer or metastatic disease.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 15, 2021
    Assignee: Neuro-Bio Ltd
    Inventors: Susan Adele Greenfield, Christopher Pepper